Tirzepatide and Ongoing Enforcement Tirzepatide (Mounjaro, Zepbound) remains on the FDA shortage list as of the date of this article's review, so compounding is still permitted under certain conditions
And we can build these very potent molecules, and its not inconceivable that we could create molecules that activate not only the GLP-1 receptor, but other anabolic receptors like myostatin and activin
Cell 176(6):12481264 Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress
So, dear readers, stay in touch as the saga of Ozempic / Wegovy vs Mounjaro continues to unfold
Tirzepatides benefit is reducing the metabolic drivers high insulin, inflammatory cytokines that amplify pain and lesion growth in patients with concurrent metabolic dysfunction
Less common but important risks include dehydration from severe vomiting or diarrhoea, gallbladder problems, pancreatitis, and worsening of diabetic eye disease in some patients with diabetes